Formycon AGCHIX:FYBD 65 Interest Coverage is 0.31 as of Dec. 2025, which is 100% below its 10-year median of 215.94. GuruFocus rates CHIX:FYBD with a GF Score™ of 65/100 and a GF Value™ of €121.24. The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, Formycon AG ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Formycon AG's
Operating Income
for the
six
months ended in Dec. 2025 was €0.89 Mil. Formycon AG's Interest Expense for the
six
months ended in Dec. 2025 was €-2.87 Mil.
Formycon AG's interest coverage for the quarter that ended in Dec. 2025 was 0.31.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Formycon AG's Interest Coverage or its related term are showing as below:
CHIX:FYBd's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Formycon AG (CHIX:FYBd) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Formycon AG Interest Coverage Related Terms
Formycon AG Interest Coverage Historical Data
* Premium members only.
The historical data trend for Formycon AG's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:FYBD vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Formycon AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Formycon AG's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (CHIX:FYBD) has a Interest Coverage of 0.31 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Formycon AG and its competitors. This is 100% below median its historical median of 215.94. According to the industry distribution chart, Formycon AG ranks #999999 out of 377 companies in the Biotechnology industry.
Is Formycon AG's Interest Coverage too high?
Formycon AG's current Interest Coverage of 0.31 is 100% below median its 10-year median of 215.94. The Biotechnology industry median Interest Coverage is 106.07. Formycon AG's value of 0.31 is 99.7% below this industry median. Based on the distribution chart, Formycon AG ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Formycon AG has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #999999 out of 377 companies for Interest Coverage. This places Formycon AG in the lower half of its industry. The industry median Interest Coverage is 106.07. Formycon AG's value of 0.31 is 99.7% below this benchmark. While the company's 10-year median is 215.94 vs. the industry median of 106.07, Formycon AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formycon AG's current Interest Coverage of 0.31 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Formycon AG and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formycon AG's current Interest Coverage is 0.31, which is 100% below median its own 10-year median of 215.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current Interest Coverage of 0.31. The stock's GF Value™ is €121.24, compared to a current price of €63.30 — trading 47.8% below its estimated fair value. The current Interest Coverage is 0.31, which is 100% below median its 10-year median of 215.94 and 99.7% below the Biotechnology industry median of 106.07. Formycon AG's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current Interest Coverage is 0.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (CHIX:FYBD) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €63.30 is trading 47.8% below its estimated GF Value™ of €121.24.
Key valuation signals for CHIX:FYBD:
Interest Coverage: 0.31 (100% below median its 10-year median of 215.94)
GF Value™: €121.24 vs. price of €63.30 (47.8% below fair value)
Industry Position: 99.7% below the Biotechnology median (#999999 of 377)
No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score
Get the complete analysis for CHIX:FYBD
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FYBD has been successfully added to your 
